ClinicalTrials.gg

Program

bretisilocin

A development code. Also written as “GM-2505”.

In AbbVie’s pipeline, Serotonin 5-HT2A receptor. Its studies are mostly in Depressive Disorder, Major, led by AbbVie.

Furthest: phase 2, since Jan 23, 20241 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie10 open or runningphase 2since Jan 23, 2024Jan 23, 2024none ahead
  • Named in AbbVie’s own pipeline as Bretisilocin, phase 2, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 23, 2024First study: phase 2 study in Depressive Disorder, MajorFirst studyNCT06236880 · 126 enrolled · United Kingdom

TargetBeta

“Serotonin 5-HT2A receptor”the company's pipeline, read by Claude · source

Other programs on HTR2A

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
paliperidoneruleJohnson & Johnsonphase 4106
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
lurasidoneruleSumitomo Pharmaphase 452
cyclobenzaprineruleTonix Pharmaceuticalsphase 432
iloperidoneruleVanda Pharmaceuticalsphase 415
lumateperoneruleJohnson & Johnsonphase 325
Psilocybinrulecompass-pathwaysphase 322
TrazodoneruleAngelini Pharmaphase 314
bretisilocinAbbViephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06236880Depressive Disorder, Major · United Kingdom2CompletedJul 27, 2026126

How it is read

Names in the registry

  • “GM-2505”, 1 entry

Codes read as this program: GM2505.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.